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Abstract
Background: Most of the circulating Vitamin D (VitD) is transported bound to vitamin D-binding protein (DBP),
and several DBP single nucleotide polymorphisms (SNPs) have been related to circulating VitD concentration and
disease. In this study, we evaluated the association among DBP SNPs and AIDS progression in antiretroviral treatment
(ART)-naïve-HIV-infected patients.
Methods: We performed a retrospective study in 667 patients who were classified according to their pattern of AIDS
progression (183 long-term non-progressors (LTNPs), 334 moderate progressors (MPs), and 150 rapid progressors (RPs))
and 113 healthy blood donors (HIV, HCV, and HBV negative subjects). We genotyped seven DBP SNPs (rs16846876,
rs12512631, rs2070741, rs2282679, rs7041, rs1155563, rs2298849) using Agena Bioscience’s MassARRAY platform. The
genetic association was evaluated by Generalized Linear Models adjusted by age at the moment of HIV diagnosis,
gender, risk group, and VDR rs2228570 SNP. Multiple testing correction was performed by the false discovery rate
(Benjamini and Hochberg procedure; q-value).
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Results: All SNPs were in HWE (p > 0.05) and had similar genotypic frequencies for DBP SNPs in healthy-controls and
HIV-infected patients. In unadjusted GLMs, we only found significant association with AIDS progression in rs16846876
and rs12512631 SNPs. In adjusted GLMs, DBP rs16846876 SNP showed significant association under the recessive
inheritance model [LTNPs vs. RPs (adjusted odds ratio (aOR) = 3.53; q-value = 0.044) and LTNPs vs. MPs (aOR = 3.28; q-
value = 0.030)] and codominant [LTNPs vs. RPs (aOR = 4.92; q-value = 0.030) and LTNPs vs. MPs (aOR = 3.15; q-value =
0.030)]. Also, we found DBP rs12512631 SNP showed significant association in the inheritance model dominant [LTNPs vs.
RPs (aOR = 0.49; q-value = 0.031) and LTNPs vs. MPs (aOR = 0.6; q-value = 0.047)], additive [LTNPs vs. RPs (aOR = 0.61; q-
value = 0.031)], overdominant [LTNPs vs. MPs (aOR = 0.55; q-value = 0.032)], and codominant [LTNPs vs. RPs (aOR = 0.52; q-
value = 0.036) and LTNPs vs. MPs (aOR = 0.55; q-value = 0.032)]. Additionally, we found a significant association between
DBP haplotypes (composed by rs16846876 and rs12512631) and AIDS progression (LTNPs vs RPs): DBP
haplotype AC (aOR = 0.63; q-value = 0.028) and the DBP haplotype TT (aOR = 1.64; q-value = 0.028).
Conclusions: DBP rs16846876 and rs12512631 SNPs are related to the patterns of clinical AIDS progression
(LTNP, MP, and RP) in ART-naïve HIV-infected patients. Our findings provide new knowledge about AIDS
progression that may be relevant to understanding the pathogenesis of HIV infection.
Keywords: Single nucleotide polymorphisms, DBP, LTNPs, AIDS, Non-progression
Background
In the absence of antiretroviral treatment (ART), human
immunodeficiency virus (HIV)-infected patients have a
highly variable progression to acquired immunodeficiency
syndrome (AIDS) [1]. Most HIV-infected patients slowly
progress towards AIDS during an extended period after
HIV seroconversion (moderate progressors, MPs). As op-
posed, extreme phenotypes regarding the virological and
clinic-immunological range of HIV disease have been de-
scribed [2]. Whereas a subgroup of HIV-infected patients
(long-term non-progressors, LTNPs) do not progress to
AIDS (absence of clinical symptoms) over an extended
period of time and have a total or partial control of HIV
replication and high CD4+ T-cells counts, others HIV-
infected patients show rapid immunological and clinical
progression within the first few years after HIV serocon-
version (rapid progressors, RPs). This variability in the
disease progression in HIV-infected patients is related to a
complex interaction among a multitude of factors, includ-
ing the immune system, genetic background, and viral
characteristics among others [3, 4].
Vitamin D (VitD) is an essential nutrient to maintain
human health, and its deficiency is related to skeletal
diseases (osteomalacia and rickets, among others) and
non-skeletal diseases (cancer, diabetes, cardiovascular dis-
eases, autoimmunity, and infectious diseases, among others)
[5]. Regarding the immune response against pathogens,
VitD triggers antimicrobial pathways in host cells and acti-
vates genes that enhance the immunity [6–8]. Hence, the
VitD deficiency is related to a higher risk of infection and
poor prognosis of infectious diseases such as tuberculosis,
influenza, fungal infections, sepsis, and HIV infection [9].
The VitD deficiency is very frequent among HIV-
infected patients (around 70–85%) and may be condi-
tioned by HIV-related factors such as ART, HIV infection
itself, and higher incidence of malnutrition and comorbid-
ities and non-HIV-related risk factors such as genetic
background, advanced age, gender, and limited sunlight
exposure [9, 10]. This VitD deficiency has been related to
high plasma viral load, increased inflammation and im-
mune activation, decreased CD4+ T-cells, and rapid AIDS
progression; whereas higher levels of VitD seem to provide
natural resistance to HIV infection [6].
Most of the circulating VitD (85–90%) is tightly bound
to vitamin D-binding protein (DBP), also known as GC
vitamin D binding protein (GC). Around 10–15% of
VitD is less tightly bound to albumin, and only a
small fraction of VitD (< 1%) circulates as “free” ster-
oid [11, 12]. VitD has a hydrophobic nature, that
binds to DBP with high affinity, particularly calcidiol
(25-hydroxycholecalciferol or 25-hydroxyvitamin D;
25(OH)D), which seems to regulate the bioavailability
of VitD [13]. The 25(OH)D is the precursor of the active
form of VitD, which is converted to the active hormone
(1,25-dihydroxycholecalciferol or 1,25-dihydroxyvitamin
D; 1,25(OH)2D) in several tissues, including cells of the
immune system. Later, the active form of VitD acts on tar-
get cells by binding to the vitamin D receptor (VDR),
which promotes gene transcription of several target genes
and other non-genomics effects [6].
The DBP gene has high variability and several single
nucleotide polymorphisms (SNPs) in DBP gene have
been linked to variations in circulating 25(OH)D con-
centration [14, 15], and chronic diseases such as chronic
obstructive pulmonary disease (COPD) and tuberculosis
[16, 17]. However, there is scarce information about the
influence of DBP SNPs on AIDS progression in naïve-
HIV-infected patients [18]. Since DBP SNPs is associated
with VitD levels, it would be plausible that DBP SNPs
could be related to AIDS progression.
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Objective
We aimed to study the association among DBP polymor-
phisms and the patterns of clinical AIDS progression




This is a retrospective study that was carried out in 667
ART-naïve HIV-infected patients included in two large
Spanish cohorts (Cohort of LTNPs and Cohort of the
Spanish AIDS Research Network (CoRIS)). Besides, 113
healthy blood donors were used as a Control-group
(HIV, hepatitis C virus (HCV), and hepatitis B virus
(HBV) negative subjects). Institutional Review Boards of
each participating centers approved the programs and all
patients signed an informed consent form. This study
was conducted under the Declaration of Helsinki and
also approved by the Research Ethics Committee of the
Instituto de Salud Carlos III (CEI PI_2010-v3).
We classified ART-naïve HIV-infected patients in
three groups by their clinical AIDS progression [19, 20]:
a) 183 LTNPs patients, who were asymptomatic over 10
years after HIV seroconversion, and with CD4+ ≥500
cells/mm3 and RNA-HIV load ≤10,000 copies/ml; b) 334
MPs patients, who had a continuous decrease in CD4+
T-cells (50–100 CD4+/mm3 per year) for at least two
years after diagnosis of HIV infection; c) 150 RPs pa-
tients, who showed two or more values of CD4+ T-cell
≤350 CD4+/mm3 and/or who had an AIDS-related event
(including death) within three years after HIV serocon-
version. HIV-infected patients were without cART dur-
ing the study period used to stratify by the pattern of
AIDS, but patients could be subsequently treated with
cART.
After blood extraction, samples were sent to the Span-
ish HIV HGM Biobank (integrated into the Spanish
AIDS Research Network (RIS) and National Netework of
Biobanks) and immediately processed and frozen after
their reception. The details of the methodology and
organization of the Spanish HIV HGM Biobank have
been described previously [21, 22]. Afterward, samples
from patients were kindly provided by the HIV BioBank
for DNA genotyping.
DNA genotyping
We selected seven DBP SNPs (rs16846876, rs12512631,
rs2070741, rs2282679, rs7041, rs1155563, rs2298849)
previously related to circulating concentrations of VitD
metabolites and non-skeletal diseases [17]. These SNPs
are located within the coding region (rs7041 [missense
variant]), the intronic region (rs2070741, rs2282679,
rs1155563 and rs2298849) and the downstream region
(rs16846876 and rs12512631) of DBP gene.
Total DNA isolation was performed from whole blood
with Wizard® SV Genomic DNA Purification System
(Promega, Madison, WI, USA). DNA genotyping was
performed at the Spanish National Genotyping Center
(http://www.cegen.org/ - CeGen) by Agena Bioscience’s
MassARRAY platform (San Diego, CA, USA) using the
iPLEX® Gold assay design system.
Statistical analysis
Statistical analyses were performed using the Statistical
Package for the Social Sciences (SPSS) 22.0 software
(IBM Corp., Chicago, USA) and Stata 15.0 (StataCorp,
Texas, USA). All p-values were two-tailed and the statistical
significance was defined as p < 0.05. For the descriptive
study, categorical data were analyzed using the chi-squared
test or Fisher’s exact test, and continuous variables were
analyzed with the Mann-Whitney U and Kruskal-Wallis
tests. The genetic association study among DBP SNPs and
clinical patterns of AIDS progression was evaluated accord-
ing to dominant, recessive, overdominant, codominant, and
additive models by Generalized Linear Models (GLMs)
with a binomial distribution (logit-link). Multiple testing
correction was performed by the false discovery rate (FDR)
with the Benjamini and Hochberg procedure (q-value) in
order to exclude spurious associations. Next, the selected
SNPs (q-value ≤0.05) were valuated by GLMs with a bino-
mial distribution (logit-link) and adjusted by age at the
moment of HIV diagnosis, gender, risk group, and VDR
rs2228570 SNP [23].
Moreover, the Hardy-Weinberg equilibrium (HWE)
and pairwise linkage disequilibrium (LD), using the stan-
dardized D’ and r2 values, were evaluated using Haploview
4.2 software (MIT/Harvard Broad Institute, Cambridge,
MA, USA) and haplotype-based association testing was
performed using PLINK software (http://zzz.bwh.harvard.
edu/plink/index.shtml) by logistic regression.
Results
Study population
The characteristics of HIV-infected patients are shown
in Table 1. The LTNPs group had the highest values of
age at the moment of HIV diagnosis (p-value < 0.001)
and at the study inclusion (p-value < 0.001), and per-
centage of intravenous drug users (IDU) (p-value <
0.001); while LTNPs group had the lowest proportion of
HIV-infected male patients (p-value < 0.001) and were
diagnosed of HIV infection before the year 2000.
Characteristics of DBP polymorphisms
Additional file 1: Table S1 shows the characteristics of
DBP polymorphisms in healthy-controls and HIV-infected
patientes. All DBP SNPs had values for minor allelic fre-
quency (MAF) higher than 5% and the DNA genotyping
call-rate success was over 95%. Besides, the genotypic and
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allelic frequencies of the DBP gene were in accordance
with the NCBI SNP database for European population
(http://www.ncbi.nlm.nih.gov/projects/SNP/). All SNPs
were in HWE (p-value > 0.05) and had similar genotypic
frequencies for DBP SNPs in healthy-controls and HIV-
infected patients.
Figure 1 shows the LD pattern for DBP polymor-
phisms in HIV-infected patients. The LD values were
low (D’ < 0.75) for rs2298849 with rs7041 (D’ = 0.10),
rs2070741 (D’ = 0.55), rs12512631 (D’ = 0.24), and
rs16846876 (D’ = 0.03); and for rs16846876 with rs7041
(D’ = 0.62) and rs1155563 (D’ = 0.68). Besides, the values
Table 1 Clinical and epidemiological characteristics of HIV infected patients and healthy donors
Controls vs. all HIV patients HIV groups of patients
Characteristics Control All HIV (*) p-value (a) LTNPs-group MPs-group RPs-group p-value(b)
No. 113 667 183 334 150
Male 93 (82.3%) 540 (81.4%) 0.829 115 (64.2%) 283 (84.7%) 142 (94.7%) < 0.001
Age (years) 42.0 (37.0; 49.0) 41.3 (35.0; 48.4) 0.427 48.7 (46.0; 51.7) 38.2 (33.2; 45.3) 38.3 (33.0; 43.8) < 0.001
Age of HIV diagnosis – 34.3 (29.0; 40.4) – 39.8 (34.3; 43.7) 31.8 (27.0; 38.4) 34.0 (29.6; 38.1) < 0.001
Year of HIV diagnosis – 2006 (1999; 2008) – 1993 (1990; 1997) 2006 (2004; 2008) 2009 (2007; 2010) < 0.001
HIV acquired
IDU – 166 (25.0%) – 130 (72.6%) 29 (8.7%) 7 (4.7%) < 0.001
Homosexual – 359 (54.1%) – 13 (7.3%) 220 (65.9%) 126 (84.0%)
Heterosexual – 118 (17.8%) – 27 (15.1%) 76 (22.8%) 15 (10.0%)
Others – 20 (3.0%) – 9 (5.0%) 9 (2.7%) 2 (1.3%)
Abbreviations: IDU Intravenous drug users, HIV Human immunodeficiency virus, LTNPs Long Term Non Progressors, MPs Moderate Progressors, RPs
Rapid progressors.
Statistics: P-values were calculated by Chi-square or Fisher’s exact test, Mann-Whitney and Kruskal-Wallis tests.
(a)differences between control group and all HIV infected patients.
(b)differences among HIV groups. Statistically significant differences are shown in bold.
(*)Clinical and epidemiological data for three HIV-infected patients were not available.
Fig. 1 Pairwise linkage disequilibrium (LD) pattern for DBP polymorphisms in HIV-infected patients. The grey color intensity decreases with
decreasing R-squared value. The location of SNPs is indicated on top. The diagonal represents a SNP and the square represents a pairwise
comparison between two SNPs, indicating the magnitude of LD (D’ and r2). D’ and r2 varies from 0 (absence) to 1 (complete). Abbreviations: DBP,
vitamin D binding protein; SNP, single nucleotide polymorphism; LD, linkage disequilibrium; r2, square of the correlation coefficient; D’; D-prime or
proportion of the possible LD that was present between two SNPs
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of r2 statistic were low (r2 < 0.75) among all DBP SNPs
except for rs2282679 and rs1155563 (r2 = 0.83), which
indicate that most SNPs provide different information.
DBP polymorphisms and AIDS progression
Figure 2 shows the association among DBP polymorphisms
and AIDS progression by unadjusted GLMs (full descrip-
tion in Additional file 2: Table S2). When comparing
LTNPs vs. MPs, rs16846876 showed significant associations
with the recessive (q-value = 0.045) and codominant (q-
value = 0.045) models; and rs12512631 showed significant
values with the dominant (q-value = 0.044), overdominant
(q-value = 0.032), and codominant (q-value = 0.032) models.
When comparing LTNPs vs. RPs, we found significant as-
sociations for rs12512631 in the dominant (p-value = 0.035)
and codominant (p-value = 0.044) models, but this signifi-
cant association disappeared after the FDR (Benjamini &
Hochberg) controlling procedure. When comparing MPs
vs. RPs, there were no significant values.
Afterwards, we evaluated the association of rs16846876
and rs12512631 polymorphisms with AIDS progression by
GLMs adjusted by age, gender, risk category, and VDR
rs2228570 SNP (Fig. 3). DBP rs16846876 SNP showed sig-
nificant association under the recessive inheritance model
[LTNPs vs. RPs (adjusted odds ratio (aOR) = 3.53; q-
value = 0.044) and LTNPs vs. MPs (aOR = 3.28; q-value =
0.030)] and codominant [LTNPs vs. RPs (aOR = 4.92; q-
value = 0.030) and LTNPs vs. MPs (aOR = 3.15; q-value =
0.030)]. We also found DBP rs12512631 SNP showed sig-
nificant association in the inheritance model dominant
[LTNPs vs. RPs (aOR = 0.49; q-value = 0.031) and LTNPs
vs. MPs (aOR = 0.6; q-value = 0.047)], additive [LTNPs vs.
RPs (aOR = 0.61; q-value = 0.031)], overdominant [LTNPs
vs. MPs (aOR = 0.55; q-value = 0.032)], and codominant
[LTNPs vs RPs (aOR = 0.52; q-value = 0.036) and LTNPs
vs. MPs (aOR = 0.55; q-value = 0.032)].
DBP haplotypes and AIDS progression
Table 2 shows the adjusted association of DBP haplo-
types (composed by rs16846876 and rs12512631) with
the patterns of AIDS progression. When comparing
LTNPs vs. RPs, we found significant associations for the
DBP haplotype AC (aOR = 0.63; q-value = 0.028) and the
DBP haplotype TT (aOR = 1.64; q-value = 0.028).
Discussion
In this study, rs16846876 and rs12512631 SNPs were as-
sociated with progression of HIV infection (LTNPs vs.
Fig. 2 Genetic association of DBP polymorphisms with AIDS progression in HIV-infected patients. Statistics: P-values were calculated by
unadjusted Generalized Linear Models (GLMs) with a binomial distribution (logit-link). (*), raw p-values; (**), p-values corrected for multiple testing
using the false discovery rate (FDR) with Benjamini and Hochberg procedure (n = 6 inheritance models, multiple comparisons). Abbreviations:
DBP, vitamin D binding protein; LTNPs, Long Term Non Progressors; MPs, Moderate Progressor; RPs, Rapid Progressor; Codominant 1, codominant
1 refers to heterozygous genotype vs more frequent homozygous (genotype 1); Codominant 2, codominant 2 refers to less frequent homozygote
(genotype 2) vs more frequent homozygote (genotype 1)
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Fig. 3 Genetic association of DBP polymorphisms with AIDS progression in HIV-infected patients. Statistics: P-values were calculated by
Generalized Linear Models (GLMs) with a binomial distribution (logit-link) and adjusted for age, gender, and risk category and rs2228570 VDR
polymorphism. (*), raw p-values; (**), p-values corrected for multiple testing using the false discovery rate (FDR) with Benjamini and Hochberg
procedure (n = 6 inheritance models, multiple comparisons). Abbreviations: DBP, vitamin D binding protein; LTNPs, Long Term Non Progressors;
MPs, Moderate Progressor; RPs, Rapid Progressor; Codominant 1, codominant 1 refers to heterozygous genotype vs. more frequent homozygous
(genotype 1); Codominant 2, codominant 2 refers to less frequent homozygote (genotype 2) vs. more frequent homozygote (genotype 1)
Table 2 Distribution of vitamin D binding protein (DBP) haplotypes (composed by rs16846876 and rs12512631) and its association
with the patterns of clinical AIDS progression (LTNPs, MPs, RPs) in HIV infected patients
Univariate Multivariate
Haplotypes Freq. aOR (95CI) p-value (*) q-value (**) aOR (95CI) p-value (*) q-value (**)
LTNPs vs MPs
AC 0.366 0.85 (0.65; 1.10) 0.218 0.284 0.85 (0.63; 1.15) 0.292 0.378
TT 0.307 1.45 (1.09; 1.93) 0.009 0.027 2.32 (4.95; 20.8) 0.018 0.054
AT 0.321 0.86 (0.66; 1.13) 0.284 0.284 0.87 (0.65; 1.18) 0.378 0.378
LTNPs vs RPs
AC 0.361 0.74 (0.53; 1.04) 0.080 0.120 0.63 (0.43; 0.93) 0.019 0.028
TT 0.286 1.43 (1.01; 2.02) 0.044 0.120 1.64 (1.09; 2.46) 0.017 0.028
AT 0.343 0.99 (0.73; 1.37) 0.973 0.973 1.07 (0.74; 1.54) 0.708 0.708
Abbreviations: aOR Adjusted odds ratio, 95 CI 95% confidence interval, HIV Human immunodeficiency virus, DBP Vitamin D binding protein, LTNPs Long term non
progressors, MPs moderate progressor, RPs Rapid progressor.
Statistics: P-values were calculated using PLINK software by logistic regression adjusted by gender, age at HIV diagnosis, men who had sex with men and VDR
rs2228570 polymorphism.
(*)raw p-values
(**)p-values corrected for multiple testing (q-value) using the false discovery rate (FDR) with Benjamini and Hochberg procedure (n = 3 haplotypes, multiple
comparisons). Statistically significant differences are shown in bold.
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MPs) and progression to AIDS (LTNPs vs. RPs) in ART-
naïve HIV-infected patients from two Spanish large co-
horts (cohorts of LTNP and CoRIS), which collected
patients from all over Spain. Besides, this last association
(LTNPs vs. RPs) was confirmed in the analysis of DBP
haplotypes (composed by rs16846876 and rs12512631).
Our study was performed in HIV-infected patients
came from all different regions of Spain. This detail is an
interesting plus of our study because the genetic diversity
that could be found in Spain is better represented. Besides,
a variability in sun exposure is also to be expected since
Spain has characteristics of seasonality and radiation that
vary between regions, which may impact in the conversion
rate of pro-vitamin D to pre-vitamin D.
The DBP gene is highly polymorphic, and some SNPs
have been linked to VitD concentration in serum of gen-
eral population [17] and HIV infected patients [24]. DBP
SNPs are associated with the delivery of 1,25(OH)2D to
target tissues, as well as the removal of VitD metabolites
from circulation [14–16]. These DBP variants may modu-
late protein expression or its activity and, thus, may affect
synthesis, distribution, and function of VitD. Two of the
SNPs more studied are rs7041 and rs4588 polymorphisms,
which are missense variants that produce different iso-
forms of the DBP protein (D (Asp) > E (Glu) and T (Thr) >
M (Met), respectively) with different affinity for VitD me-
tabolites [25, 26]. These isoforms seem to affect the deliv-
ery of VitD at the cellular levels or tissues [16]. The
analysis of HapMap data shows that there are a very high
number of SNPs that are in LD with rs7041 and rs4588,
and therefore other SNPs could also be related to this
effect [18]. Besides, other DBP SNPs, as those analyzed
in this study (rs16846876, rs12512631, rs2070741,
rs2282679, rs1155563, and rs2298849), have already
been related to variations in circulating 25(OH)D con-
centration [17]. Furthermore, some of these SNPs have
been related to osteoporosis, cancer, diabetes, neurode-
generative disorders, autoimmunity, asthma, COPD,
and tuberculosis [17, 18]. Regarding HIV infection,
there are scarce reports about DBP SNPs and AIDS
progression in naïve-HIV-infected patients, whose have
found contradictory results [18]. Several articles did not
find any significant association between DBP SNPs and
the clinical progression of HIV infection [27–33]; while
only one report found a significant association between
DBP SNPs and AIDS progression in naïve-HIV-infected
patients [34], which coincide with our findings.
In our study, we described a significant association be-
tween rs16846876 and rs12512631 SNPs and clinical
progression of HIV infection. Regarding the possible ac-
tion mechanism of the studied polymorphisms, the DBP
rs12512631 polymorphism has been linked to the
methylation status of the DBP gene, possibly affecting
gene transcription and phenotypic characteristics [35].
In the literature, several studies found an association
between the rs12512631 polymorphism and serum
25(OH)D concentration in the healthy population [36]
and in the cancer patients [16, 35]. Besides, differences in
the strength of the association between rs12512631 and
25(OH)D concentration seem to vary according to the pa-
tient characteristics [37]. In this setting, Miettinen et al.
[37] reported a significant association of rs12512631 with
25(OH)D concentration in the mothers of type 1 diabetic
children, while there was no association in the mothers of
non-diabetic children during pregnancy. Additionally,
rs12512631 was associated with 25(OH)D levels in differ-
ent ways in young people and adults [37]. In these studies,
rs12512631 C allele was associated with high concentra-
tion of VitD [36, 37], which conceptually agrees with our
data. The presence of C allele was associated with protec-
tion against progression of HIV infection (LTNPs vs.
MPs) and progression to AIDS (LTNPs vs. RPs), possibly
because the plasma VitD concentration in these patients
was higher. The DBP rs16846876 polymorphism has been
also linked to serum 25(OH) D concentrations in healthy
subjects [36], pregnant women [38], and cancer patients
[16]. In the literature, rs16846876 TT genotype was asso-
ciated with lower concentration of VitD [36, 38], which is
in acordance with our results. The presence of TT geno-
type was associated with higher odds of progression of
HIV infection (LTNPs vs. MPs), possibly because the
plasma VitD concentration was lower than in presence of
AA and AT genotypes. Little is known about DBP
rs16846876 polymorphism and its possible role on gene
expression or another molecular mechanism. By using
HaploReg v4.1 software (https://pubs.broadinstitute.org/
mammals/haploreg/haploreg.php), which is a bioinfor-
matic tool for exploring candidate regulatory SNPs on
haplotype blocks, we found that DBP rs16846876 poly-
morphism is in high LD with several SNPs such as
rs11732044, rs12648331, rs56003670, rs60696209 and
rs2201124, which are involved in histone modifications
with enhancer properties. Histone modifications can alter
chromatine structure, which determines the DNA accessi-
bility. The actively transcribed regions are usually located
in looser chromatin regions, so RNA polymerases and
transcription factors can access more easily. In this con-
text, the observed role of the rs16846876 polymorphism
on the HIV progression could be related with epigenetic
changes in an indirect way, reflecting the regulation of
DBP expression caused by SNPs in high LD with
rs16846876 polymorphism.
Moreover, in the current study, DBP haplotypes (com-
prised of rs16846876 and rs12512631) were also investi-
gated to analyze the association with HIV progression.
Patients with TT haplotype (unfavorable alleles) had two
twice more odds of HIV progression, while patients AC
haplotype (favorable alleles) had decreased odds. These
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associations confirm the previous findings for individual
SNPs. However, the results obtained with the analysis of
haplotypes did not improve those obtained for individual
SNPs, where we found that patients carrying the
rs16846876 TT genotype had a probability of around
four times more HIV progression than patients carrying
AA or AT genotype.
Limitations of the study
Firstly, the limited number of patients per group that
may have decreased the statistical power and the num-
ber of significant values, particularly after FDR control-
ling multiple testing. Secondly, the differences between
the three groups of patients (LTNPs, MPs, and RPs) in
demographic and clinical characteristics were substantial
and they could have introduced some bias in the study,
although we accounted for these variables in the statis-
tical analysis. This is due to the idiosyncrasy of each
group. Thirdly, we did not have data of DBP and VitD in
the plasma because the adequate sample was not avail-
able in most patients. Besides, non-AIDS-related comor-
bidities were not available, particularly information
about liver disease which directly affects to DBP levels in
the body.
Conclusions
DBP rs16846876 and rs12512631 SNPs are related to the
patterns of clinical AIDS progression (LTNPs, MPs, and
RPs) in ART-naïve HIV-infected patients. Our findings
provide new knowledge about AIDS progression that
may be relevant to a better understanding of the patho-
genesis of HIV infection.
Appendix 1
Annex: Centers and investigators involved in CoRIS
Executive committee: Santiago Moreno, Julia del Amo,
David Dalmau, Maria Luisa Navarro, Maria Isabel
González, Jose Luis Blanco, Federico Garcia, Rafael
Rubio, Jose Antonio Iribarren, Félix Gutiérrez, Francesc
Vidal, Juan Berenguer, Juan González.
Fieldwork, data management and analysis: Julia Del
Amo, Inma Jarrín, Belén Alejos, Victoria Hernando,
Cristina Moreno, Carlos Iniesta, Luis Miguel Garcia
Sousa, Nieves Sanz Perez.
BioBanK HIV: Hospital General Universitario Gregorio
Marañón: M Ángeles Muñoz-Fernández, Isabel María
García-Merino, Irene Consuegra Fernández, Coral Gómez
Rico, Jorge Gallego de la Fuente, Paula Palau Concejo.
Participating centres:
Hospital General Universitario de Alicante (Alicante):
Joaquín Portilla, Esperanza Merino, Sergio Reus, Vicente
Boix, Livia Giner, Carmen Gadea, Irene Portilla, María
Pampliega, Marcos Díez, Juan Carlos Rodríguez, José
Sánchez-Payá.
Hospital Universitario de Canarias (San Cristobal
de la Laguna): Juan Luis Gómez, Jehovana Hernández,
María Remedios Alemán, María del Mar Alonso, María
Inmaculada Hernández, Felicitas Díaz-Flores, Dácil García,
Ricardo Pelazas., Ana López Lirola.
Hospital Universitario Central de Asturias (Oviedo):
José Sanz Moreno, Alberto Arranz Caso, Cristina
Hernández Gutiérrez, María Novella Mena.
Hospital Universitario 12 de Octubre (Madrid):
Rafael Rubio, Federico Pulido, Otilia Bisbal, Asunción
Hernando, Lourdes Domínguez, David Rial Crestelo,
Laura Bermejo, Mireia Santacreu.
Hospital Universitario de Donostia (Donostia-San
Sebastián): José Antonio Iribarren, Julio Arrizabalaga,
María José Aramburu, Xabier Camino, Francisco
Rodríguez-Arrondo, Miguel Ángel von Wichmann,
Lidia Pascual Tomé, Miguel Ángel Goenaga, Mª Jesús
Bustinduy, Harkaitz Azkune, Maialen Ibarguren, Aitziber
Lizardi, Xabier Kortajarena.
Hospital General Universitario De Elche (Elche):
Félix Gutiérrez, Mar Masiá, Sergio Padilla, Andrés
Navarro, Fernando Montolio, Catalina Robledano, Joan
Gregori Colomé, Araceli Adsuar, Rafael Pascual, Marta
Fernández, Elena García, José Alberto García, Xavier
Barber.
Hospital General Universitario Gregorio Marañón
(Madrid): Juan Berenguer, Juan Carlos López Bernaldo
de Quirós, Isabel Gutiérrez, Margarita Ramírez, Belén
Padilla, Paloma Gijón, Teresa Aldamiz-Echevarría, Fran-
cisco Tejerina, Francisco José Parras, Pascual Balsalobre,
Cristina Diez, Leire Pérez Latorre.
Hospital Universitari de Tarragona Joan XXIII
(Tarragona): Francesc Vidal, Joaquín Peraire, Consuelo
Viladés, Sergio Veloso, Montserrat Vargas, Miguel
López-Dupla, Montserrat Olona, Anna Rull, Esther
Rodríguez-Gallego, Verónica Alba.
Hospital Universitario y Politécnico de La Fe
(Valencia): Marta Montero Alonso, José López Aldeguer,
Marino Blanes Juliá, María Tasias Pitarch, Iván Castro
Hernández, Eva Calabuig Muñoz, Sandra Cuéllar Tovar,
Miguel Salavert Lletí, Juan Fernández Navarro.
Hospital Universitario La Paz/IdiPAZ: Juan González-
garcia, Francisco Arnalich, José Ramón Arribas, Jose
Ignacio Bernardino de la Serna, Juan Miguel Castro,
Luis Escosa, Pedro Herranz, Victor Hontañón, Silvia
García-Bujalance, Milagros García López-Hortelano,
Alicia González-Baeza, Maria Luz Martín-Carbonero,
Mario Mayoral, Maria Jose Mellado, Rafael Esteban
Micán, Rocio Montejano, María Luisa Montes,
Victoria Moreno, Ignacio Pérez-Valero, Berta Rodés,
Talia Sainz, Elena Sendagorta, Natalia Stella Alcáriz,
Eulalia Valencia.
Hospital San Pedro Centro de Investigación Biomé-
dica de La Rioja (CIBIR) (Logroño): José Ramón Blanco,
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José Antonio Oteo, Valvanera Ibarra, Luis Metola, Merce-
des Sanz, Laura Pérez-Martínez.
Hospital Universitari MutuaTerrassa (Terrasa):
David Dalmau, Angels Jaén, Montse Sanmartí, Mireia
Cairó, Javier Martinez-Lacasa, Pablo Velli, Roser Font,
Mariona Xercavins, Noemí Alonso.
Complejo Hospitalario de Navarra (Pamplona):
María Rivero, Jesús Repáraz, María Gracia Ruiz de Alda,
María Teresa de León Cano, Beatriz Pierola Ruiz de
Galarreta.
Corporació Sanitària Parc Taulí (Sabadell): Ferrán
Segura, María José Amengual, Gemma Navarro,
Montserrat Sala, Manuel Cervantes, Valentín Pineda,
Sonia Calzado, Marta Navarro.
Hospital Universitario de La Princesa (Madrid):
Ignacio de los Santos, Jesús Sanz Sanz, Ana Salas Aparicio,
Cristina Sarriá Cepeda, Lucio Garcia-Fraile Fraile, Enrique
Martín Gayo.
Hospital Universitario Ramón y Cajal (Madrid):
Santiago Moreno, José Luis Casado, Fernando Dronda,
Ana Moreno, María Jesús Pérez Elías, Cristina Gómez
Ayerbe, Carolina Gutiérrez, Nadia Madrid, Santos del
Campo Terrón, Paloma Martí, Uxua Ansa, Sergio Serrano,
María Jesús Vivancos.
Hospital General Universitario Reina Sofía
(Murcia): Enrique Bernal, Alfredo Cano, Antonia
Alcaraz García, Joaquín Bravo Urbieta, Ángeles Muñoz,
Maria Jose Alcaraz, Maria del Carmen Villalba.
Hospital Nuevo San Cecilio (Granada): Federico
García, José Hernández, Alejandro Peña, Leopoldo
Muñoz, Paz Casas, Marta Alvarez, Natalia Chueca, David
Vinuesa, Clara Martinez-Montes.
Centro Sanitario Sandoval (Madrid): Jorge Del
Romero, Carmen Rodríguez, Teresa Puerta, Juan
Carlos Carrió, Mar Vera, Juan Ballesteros, Oskar
Ayerdi.
Hospital Universitario Son Espases (Palma de
Mallorca): Melchor Riera, María Peñaranda, María
Leyes, Mª Angels Ribas, Antoni A Campins, Carmen
Vidal, Francisco Fanjul, Javier Murillas, Francisco
Homar.
Hospital Universitario Virgen de la Victoria
(Málaga): Jesús Santos, Crisitina Gómez Ayerbe, Isabel
Viciana, Rosario Palacios, Carmen María González.
Hospital Universitario Virgen del Rocío (Sevilla):
Pompeyo Viciana, Nuria Espinosa, Luis Fernando López-
Cortés.
Hospital Universitario de Bellvitge (Hospitalet de
Llobregat): Daniel Podzamczer, Elena Ferrer, Arkaitz
Imaz, Juan Tiraboschi, Ana Silva, María Saumoy.
Hospital Costa del Sol (Marbella): Julián Olalla,
Alfonso del Arco, Javier de la torre, José Luis Prada,
José María García de Lomas Guerrero, Javier Pérez
Stachowski.
Hospital General Universitario Santa Lucía (Carta-
gena): Onofre Juan Martínez, Francisco Jesús Vera,
Lorena Martínez, Josefina García, Begoña Alcaraz,
Amaya Jimeno.
Complejo Hospitalario Universitario a Coruña
(Chuac) (A Coruña): Angeles Castro Iglesias, Berta
Pernas Souto, Alvaro Mena de Cea.
Hospital Universitario Virgen de la Arrixaca (El
Palmar): Carlos Galera, Helena Albendin, Aurora Pérez,
Asunción Iborra, Antonio Moreno, Maria Angustias
Merlos, Asunción Vidal.
Hospital Universitario Infanta Sofia (San Sebastian
de los Reyes): Inés Suárez-García, Eduardo Malmierca,
Patricia González-Ruano, Dolores Martín Rodrigo.
Complejo Hospitalario de Jaén (Jaén): Mohamed
Omar Mohamed-Balghata, María Amparo Gómez Vidal.
Hospital Clínico San Carlos (Madrid): Vicente
Estrada Pérez, Maria Jesus Téllez Molina, Jorge Vergas
García, Juncal Pérez-Somarriba Moreno.
Hospital Universitario Fundación Jiménez Díaz
(Madrid): Miguel Górgolas., Alfonso Cabello., Beatriz
Álvarez., Laura Prieto.
Hospital Universitario Príncipe de Asturias (Alcalá
de Henares): José Sanz Moreno, Alberto Arranz Caso,
Cristina Hernández Gutiérrez, María Novella Mena.
Hospital Clínico Universitario de Valencia (València):
María José Galindo Puerto, Ramón Fernando Vilalta, Ana
Ferrer Ribera.
Hospital Reina Sofía (Córdoba): Antonio Rivero
Román, Maria Teresa Brieva Herrero, Antonio Rivero
Juárez, Pedro López López, Isabel Machuca Sánchez,
José Peña Martínez.
Hospital Universitario Severo Ochoa (Leganés):
Miguel Cervero Jiménez, Rafael Torres Perea, Juan José
Jusdado Ruiz-Capillas.
Nuestra Señora de Valme: Juan A Pineda.
Appendix 2
Centers involved in Long Term Non-Progressors
(LTNP) chort:
C. Sandoval - Madrid.
H. 12 de Octubre - Madrid.
H. Arnau de Vilanova - Lleida.
H. Asturias.
H. Bellvitge - Barcelona.
H. Castellón.
H. Clínic - Barcelona.
H. Donostia - San Sebastián.
H. Elche - Alicante.
H. Germans Trias i Pujol - Badalona.
H. Gregorio Marañón - Madrid.
H. Joan XXIII - Tarragona.
H. La Fe - Valencia.
H. La Paz/Carlos III - Madrid.
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H. La Princesa - Madrid.
H. Navarra - Pamplona.
H. Parc Taulí- Sabadell.
H. Ramón y Cajal - Madrid.
H. San Cecilio - Granada.
H. San Pedro - Logroño.
H. Son Dureta - Mallorca.
H. Virgen del Rocío – Sevilla
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